New hope for tough prostate cancers: first human trial begins
NCT ID NCT05997615
Summary
This is the first human study testing an experimental drug called VIR-5500 for advanced prostate cancer that has stopped responding to standard treatments. Researchers will enroll 390 men to check if the drug is safe, how it moves through the body, and whether it shows early signs of fighting the cancer. The study will test VIR-5500 alone and combined with other prostate cancer medications over approximately four years.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HORMONE-REFRACTORY PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Investigational Site Number: 100
RECRUITINGMelbourne, 3000, Australia
-
Investigational Site Number: 101
RECRUITINGSydney, 2010, Australia
-
Investigational Site Number: 250
RECRUITINGBarcelona, 08035, Spain
-
Investigational Site Number: 251
WITHDRAWNBarcelona, 08023, Spain
-
Investigational Site Number: 252
RECRUITINGMadrid, 28223, Spain
-
Investigational Site Number: 253
RECRUITINGPamplona, 31008, Spain
-
Investigational Site Number: 254
RECRUITINGMadrid, 28027, Spain
-
Investigational Site Number: 300
RECRUITINGLondon, SM2 5PT, United Kingdom
-
Investigational Site Number: 400
RECRUITINGSeattle, Washington, 98109, United States
Conditions
Explore the condition pages connected to this study.